Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Challenges in urothelial cell carcinoma

Alison Birtle • 15 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer

Alison Birtle, MBBS, MRCP, FRCR, MD, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK, discusses the real-world challenges in urothelial carcinoma and how these can be addressed at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Alison Birtle

Trial updates from ASCO GU 2021: SPIRE, NEO-BLADE, P3BEP and SAPROCAN
3:52
Trial updates from ASCO GU 2021: SPIRE, NEO-BLADE, P3BEP and SAPROCAN
Alison Birtle • 16 Feb 2021
POUT: extended follow-up results
10:05
POUT: extended follow-up results
Alison Birtle • 16 Feb 2021
ASCO GU 2021 highlights: enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617
0:50
ASCO GU 2021 highlights: enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617
Alison Birtle • 16 Feb 2021
Alison Birtle: ASCO GU highlights
1:53
Alison Birtle: ASCO GU highlights
Alison Birtle • 13 Feb 2020

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals